Clinical Trials Logo

Leukemia, Myeloid clinical trials

View clinical trials related to Leukemia, Myeloid.

Filter by:

NCT ID: NCT01019317 Completed - Leukemia Clinical Trials

Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Start date: November 2009
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if the combination of fludarabine and cytarabine can help to control Acute Myelogenous Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myeloid Leukemia (CML) in myeloid blast crisis. The safety of this drug combination will also be studied.

NCT ID: NCT01019161 Completed - Clinical trials for Acute Myeloid Leukaemia

An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)

Start date: November 2009
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess how AZD1152 is absorbed or excreted in and out of the body in patients with Acute Myeloid Leukaemia (AML).

NCT ID: NCT01016600 Completed - Clinical trials for Leukemia, Myeloid, Acute

Azacitidine and Lenalidomide for Acute Myeloid Leukemia

Start date: April 2010
Phase: Phase 1/Phase 2
Study type: Interventional

Determine toxicity and remission rates of treatment with azacitidine and lenalidomide for patients with Acute Myeloid Leukemia

NCT ID: NCT01015742 Recruiting - Clinical trials for Leukemia, Myeloid, Acute

Unrelated Double Umbilical Cord Blood Units Transplantation

Start date: November 2009
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine the safety and feasibility of unrelated double umbilical cord blood units Transplantation in patients with haematological malignancies using Antithymocyte Globulin Cyclophosphamide, busulfan as conditioning and cyclosporin, methylprednisolone as GVHD prophylaxis.

NCT ID: NCT01015196 Completed - Clinical trials for Acute Myeloid Leukemia

Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell Transplantation

AML2001
Start date: January 2001
Phase: Phase 2/Phase 3
Study type: Interventional

First randomization: After inclusion Use of Daunorubicin (arm D) or Idarubicin (arm I) as anthracyclin during all courses of chemotherapy (induction, consolidation courses before ASCT) Second randomization: After achieving 1st CR: all patients received non intensive consolidation course Familial HLA typing required for all patients Patients with HLA-identical sibling: Patients with very good prognostic factors (CBF leukemias, WBC < 30 giga/l at diagnosis, 1st CR after one induction course) = arm C: no allogeneic stem cell transplantation in 1st CR; received 2 more courses of intensive consolidation chemotherapy All others patients received an allogeneic transplant For patients aged less than 51 = arm M: upfront myeloablative conditioning regimen For patients aged over 51 and less than 61= arm m: intensive chemotherapy consolidation course.

NCT ID: NCT01011998 Withdrawn - Clinical trials for Chronic Myelogenous Leukemia

A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)

Start date: September 2009
Phase: Phase 2
Study type: Interventional

The aim of this study is to test the effect of the combination of valproate in combination with imatinib with an aim of achieving a maximal molecular response as the primary goal.

NCT ID: NCT01010373 Suspended - Clinical trials for Acute Myeloid Leukemia

Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients

Start date: January 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether addition of AS101 to the standard chemotherapy regimen is effective in the treatment of newly diagnosed elderly (≥60) AML patients and AML transformed myelodysplastic syndrome (MDS) patients.

NCT ID: NCT01005277 Completed - Clinical trials for Secondary Acute Myeloid Leukemia

Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Start date: April 17, 2002
Phase:
Study type: Observational

This research study is looking at biomarkers in DNA samples from patients with acute lymphoblastic leukemia or acute myeloid leukemia. Studying samples of DNA from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.

NCT ID: NCT01004965 Completed - Leukemia Clinical Trials

Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720

Start date: March 15, 1997
Phase:
Study type: Observational

This research study is looking at bone marrow and blood samples in patients with untreated acute myeloid leukemia or acute lymphoblastic leukemia enrolled on clinical trial CALGB-9621, CALGB-9720, CALGB 19808, and CALGB 10201. Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

NCT ID: NCT01003054 Completed - Clinical trials for Chronic Myelogenous Leukemia

Autologous Transplantation for Chronic Myelogenous Leukemia

Start date: March 2005
Phase: Phase 2
Study type: Interventional

The goal of this clinical research is to learn if treatment with high-dose busulfan and cyclophosphamide plus autologous bone marrow transplantation followed by treatment with Gleevec (imatinib mesylate) is effective in treating chronic myelogenous leukemia (CML). Objectives: 1. To assess the efficacy of high dose busulfan-cyclophosphamide and autologous hematopoietic transplantation with post transplant Imatinib mesylate for the treatment of CML. The primary endpoint of the study is to determine the proportion of patients with CML alive in cytogenetic remission at one year following this treatment. 2. Secondary endpoints are time to progression and survival.